会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • AMINO ACID-DERIVED COMPOUNDS AS MODULATORS OF THE REVERSE CHOLESTEROL TRANSPORT
    • 氨基酸衍生化合物作为反向胆固醇运输的调节剂
    • WO2006049597A1
    • 2006-05-11
    • PCT/US2004/035749
    • 2004-10-27
    • AVANIR PHARMACEUTICALSSIRCAR, Jagadish, C.ALISALA, KashinathamNIKOULIN, Igor
    • SIRCAR, Jagadish, C.ALISALA, KashinathamNIKOULIN, Igor
    • C07K14/775
    • C07K5/0817A61K38/06A61K38/07A61K38/08C07K5/06139C07K5/0812C07K5/0819C07K5/1016C07K5/1019C07K5/1021C07K14/775Y02P20/55
    • The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral ,delivery and useful in the treatment and/or prevention of disease conditions associated with hypercholesterolemia. For example, the compositions contain one of the following active agents: i) a compound comprising between 3 and 10 L or D amino acid residues or anal thereof, said compound having an amino and a carboxy terminal, and comprising the sequence: Xl-X2-X3, wherein X1 is an acidic amino acid, X2 a lipophilic or aromatic amino acid, and X3 is a basic amino acid, and wherein X1, X2 and X3 may be arranged in any sequential order; wherein at least one of X1, X2 or X3 further comprises a peptidomimetic modification and wherein at least one of the amino or carboxy terminals further compri a protecting group; or ii)A substantially pure amino acid-derived compound having an amino and a carboxy terminal and comprising an L or D enantiomer of an acidic amino a residue or peptidomimetic modification thereof, an L or D enantiomer of a lipophilic or aromatic amino acid residue or peptidomimetic modification thereof, and an L or D enantiomer of a basic amino acid residue or peptid mimetic modification thereof; wherein the amino and the carboxy terminal comprise a first and a second protecting group; and wherein said compound has at least one of the following properties: (1) it mimicks ApoA-I bindi to LDL and HDL, (2) it binds preferentially to liver, (3) it enhances LDL uptake by liver LDL-receptors, (4) it lower the levels of LDL, IDL, and V cholesterol, (5) it enhances cholesterol efflux from macrophages and ther inhibits foam cell formation, (6) it reduces plaque formation, (7) it increases the levels of HDL cholesterol, and (8) it improves plasma lipo­protein profiles.
    • 本发明提供适于增强哺乳动物逆转胆固醇转运的组合物。 所述组合物适合于口服,递送并且可用于治疗和/或预防与高胆固醇血症相关的疾病状况。 例如,组合物含有以下活性剂之一:i)包含3至10L或D氨基酸残基或其分析物的所述化合物,所述化合物具有氨基和羧基末端,并且包含以下序列:X1-X2 -X3,其中X1是酸性氨基酸,X2是亲脂性或芳香族氨基酸,X3是碱性氨基酸,并且其中X1,X2和X3可以以任何顺序排列; 其中X 1,X 2或X 3中的至少一个还包含拟肽修饰,并且其中所述氨基或羧基末端中的至少一个还包含保护基; 或ii)具有氨基和羧基末端并且包含酸性氨基酸残基或其拟肽修饰的L或D对映异构体的基本上纯的氨基酸衍生化合物,亲脂性或芳族氨基酸残基的L或D对映体,或 其拟肽修饰,以及碱性氨基酸残基或其肽模拟修饰的L或D对映异构体; 其中所述氨基和所述羧基末端包含第一和第二保护基团; 并且其中所述化合物具有以下性质中的至少一种:(1)它模拟与LDL和HDL结合的ApoA-I,(2)其优先结合肝脏,(3)其增强肝脏LDL受体的LDL摄取, 4)降低LDL,IDL和V胆固醇水平;(5)增强巨噬细胞胆固醇流出,抑制泡沫细胞形成,(6)减少斑块形成,(7)提高HDL胆固醇水平, 和(8)它改善了血浆脂蛋白谱。
    • 7. 发明申请
    • 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE'S AND 3-SUBSTITUTED 1,3-PYRIMIDINONE'S FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
    • 3-取代的1,2,3-三嗪-4-酮和3-取代的1,3-嘧啶酮用于增强谷氨酰胺能突触反应
    • WO2009038752A2
    • 2009-03-26
    • PCT/US2008/010877
    • 2008-09-19
    • CORTEX PHARMACEUTICALS, INC.MUELLER, RudolfSTREET, Leslie, J.RACHWAL, StanislawALISALA, Kashinatham
    • MUELLER, RudolfSTREET, Leslie, J.RACHWAL, StanislawALISALA, Kashinatham
    • C07D255/04
    • C07D487/04
    • This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke- induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
    • 本发明涉及用于预防和治疗脑功能不全的化合物,药物组合物和方法,包括增强负责基本和更高级行为的脑网络中的突触中的受体功能。 这些参与调节呼吸的脑网络以及与记忆障碍有关的认知能力,诸如在各种痴呆症中观察到的,在不同大脑区域之间的神经元活动的不平衡中,如帕金森病, 精神分裂症,呼吸抑制,睡眠呼吸暂停,注意力缺陷多动障碍和情感或情绪障碍,以及涉及神经营养因子缺乏的障碍,以及呼吸障碍如过量饮酒,阿片制剂,阿片类药物, 巴比妥类药物,麻醉剂或神经毒素,或者其中呼吸抑制导致形成诸如中枢性睡眠呼吸暂停,中风性睡眠呼吸暂停,阻塞性睡眠呼吸暂停,先天性换气不足综合征,肥胖性低通气综合征,婴儿猝死综合征 ,Rett综合征,脊髓损伤,创伤性脑损伤,Cheney-Stokes呼吸,Ondines诅咒 e,Prader-Willi综合症和溺水。 在一个特定方面,本发明涉及可用于治疗这些病症的化合物,以及使用这些化合物进行这种治疗的方法。